Adding formoterol to budesonide in moderate asthmatics is cost saving - Results from the FACET Study

E. Ståhl; Fredrik Andersson; Peter J Barnes; Claes-Göran Löfdahl; Paul M. O’Byrne; Ruben Pauwels; D.S. Postma; A. E. Tattersfield; A. Ullman

Related publications

Article2001

Adding formoterol to budesonide in moderate asthma—health economic results from the FACET study

Fredrik Andersson, E. Ståhl, Peter J Barnes, C.-G. Löfdahl, Paul M. O’Byrne, Ruben Pauwels, Dirkje S. Postma, Anne E. Tattersfield, A. Ullman

Article2000

305 A high dose of inhaled budesonide is more cost-effective than a low dose in moderate asthma

Fredrik Andersson, Sixten Borg, Peter J Barnes, C.-G Lödfdahl, Paul M. O’Byrne, Dirkje Postma, Ruben Pauwels, A. E. Tattersfield, A. Ullman

Article2021

Safety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies

J. Mark FitzGerald, Paul M. O’Byrne, Eric D. Bateman, Peter J Barnes, Jinping Zheng, Stefan Ivanov, Rosa Lamarca, Ulrika Larsdotter, Ulrika Emerath, Gerreke Jansen, Margareta Puu, Vijay K. T. Alagappan, Filip Surmont, Helen K. Reddel

Article2017

The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials

Paul M. O’Byrne, J. Mark FitzGerald, Nan-shan Zhong, Eric D. Bateman, Peter J Barnes, Christina Keen, Gun Almqvist, Kristine Pemberton, Carin Jorup, Stefan Ivanov, Helen K. Reddel

Article2013

Increased Mortality Associated With Moderate Hyperbilirubinemia in Critically Ill Patients: Results From a Large Multicenter Study

Charalampos Pierrakos, Dimitris Velissaris, Thierry Gustot, Daniel Kett, Philippe Vanhems, Peter Felleiter, Ioana Grigoraș, Yasser Sakr, Jean Louis Vincent